Medicine for inducing solid tumor differentiation and application thereof

By inducing tumor cell differentiation using the α-glucosidase inhibitor miglitol, the problem of insufficient differentiation therapy for solid tumors in the prior art was solved, and the high differentiation of tumor cells and the improvement of the effects of traditional therapies was achieved, and clinically safe and universality.

CN118924748AInactive Publication Date: 2024-11-12GUANGZHOU BIOSYNGEN CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202410975923.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art is difficult to effectively improve the degree of differentiation of solid tumors, especially in tumors of epithelial origin. It is extremely difficult to target specific mutations to achieve tumor differentiation. Currently, there is no differentiation therapy for solid tumors that can be used in clinical practice.

Method used

Miglitol, an α-glucosidase inhibitor, was used to induce tumor cell differentiation, reduce the degree of plasticity and malignancy of the tumor, and use it in combination with traditional therapies to improve the therapeutic effect.

Benefits of technology

Miglitol significantly increased the degree of differentiation of tumor cells, enhanced the response rate to traditional therapies, significantly prolonged the survival time of mice, and had no adverse reactions in clinical applications, and increased the proportion of complete remission in patients with bladder cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004954503180000011
    Figure HDA0004954503180000011
  • Figure HDA0004954503180000021
    Figure HDA0004954503180000021
Patent Text Reader

Abstract

The invention relates to a medicine for inducing solid tumor differentiation and application thereof. Specifically, the inventor provides a scheme for treating solid tumors in combination with administration of miglittol. Mitigtol can induce solid tumor cells to differentiate, so that the tumor cells are in a highly differentiated state, the plasticity of tumors is reduced, and the malignant progression of the tumors is inhibited. Mitigtol and other tumor therapies are applied at the same time, the tumor killing effect can be improved, and the response degree of tumor patients to various tumor killing strategies is increased. The combination therapy can be used for treating and / or relieving various solid tumors, and shows excellent treatment effects in in-vitro experiments, mouse model tests and clinical tests.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to a drug for inducing differentiation of solid tumors and application thereof. Background Art

[0002] The uncontrollable malignant evolution of solid tumors is one of the main difficulties faced by the frontline of clinical tumor treatment. For example, after endocrine treatment, prostate cancer often inevitably develops into androgen-resistant type; targeted drugs or anti-estrogen endocrine therapy for breast cancer cannot prevent, and even promotes the occurrence of triple-negative breast cancer to a certain extent; similar situations are also seen in radioactive iodine-resistant thyroid cancer. For solid tumors that have broken through the local area at the time of initial diagnosis, traditional therapies such as local surgery, radical surgery, chemotherapy and radiotherapy all have the common problem of insufficient response rate. When the tumor recurs, it is easy to progress to a more malignant subtype, and eventually develop into irreversible metastatic lesions that are unresponsive to all types of therapies. In view of the characteristics of the malignant evolution of solid tumors, there is currently no effective response plan in clinical treatment.

[0003] As tumor researchers delve deeper into the fate of tumor cells, it has been shown that the occurrence and development of tumors is a reverse developmental process, that is, gradually evolving toward the source of differentiation of their own lineage. The normal development and differentiation process is a process in which cell plasticity gradually decreases. Therefore, inducing cancer cells to differentiate again can theoretically eliminate tumor plasticity, thereby increasing the benefits of treatment. As early as 1959, the work conducted by Pierce's team at the University of Michigan on teratomas had conceptually confirmed the feasibility of this idea: after isolating teratoma cells, they can be induced in vitro to become a variety of normal morphological and functional tissues, and these cells can be used to repair tissue defects in mice without redeveloping into cancer in the long term.

[0004] However, this idea is difficult to extend to other cancers, especially solid tumors of epithelial origin, whose genomic changes are much more complex than APL, and whose methods of escaping differentiation pressure are more diverse. Therefore, achieving tumor differentiation by targeting specific mutations is extremely difficult in epithelial tumors, and no differentiation therapy for solid tumors has been used clinically so far.

[0005] Therefore, there is an urgent need in the art to develop drugs and applications that can improve the degree of differentiation of solid tumors. Summary of the invention

[0006] The purpose of the present invention is to provide a drug capable of improving the degree of differentiation of solid tumors and its application.

[0007] In a first aspect of the present invention, there is provided a use of an α-glucosidase inhibitor, Miglitol, for preparing a reagent or a pharmaceutical composition, wherein the reagent or the pharmaceutical composition is used for an application selected from the group consisting of:

[0008] (1) Improve the differentiation of tumor cells;

[0009] (2) reducing the malignancy of tumor cells; and / or

[0010] (3) Combined administration with other tumor therapies to treat or alleviate tumors.

[0011] In another preferred embodiment, the degree of malignancy includes: migration, invasiveness, drug resistance, or a combination thereof.

[0012] In another preferred embodiment, the other tumor therapies include: chemotherapy, radiotherapy, immunotherapy, surgical treatment, targeted drug therapy, or a combination thereof.

[0013] In another preferred embodiment, the chemotherapy is platinum-based chemotherapy, including: cisplatin, nedaplatin, carboplatin, or a combination thereof.

[0014] In another preferred embodiment, the chemotherapy is neoadjuvant chemotherapy.

[0015] In another preferred embodiment, the neoadjuvant chemotherapy refers to platinum-based chemotherapy combined with gemcitabine.

[0016] In another preferred embodiment, the immunotherapy comprises administering an immune checkpoint inhibitor, wherein the immune checkpoint inhibitor comprises: a PD-1 / PD-L1 inhibitor, a TIGHT inhibitor, a CTLA-4 inhibitor, or a combination thereof.

[0017] In another preferred embodiment, the immunotherapy comprises administering Bacillus Calmette-Guerin (BCG).

[0018] In another preferred embodiment, the targeted drug includes: FGFR inhibitors, VEGF inhibitors, EGFR inhibitors, antibody-drug conjugates (ADCs), or a combination thereof.

[0019] In another preferred embodiment, the tumor is a solid tumor.

[0020] In another preferred embodiment, the tumor is selected from the following group: bladder cancer, prostate cancer, breast cancer, thyroid cancer, lung cancer, esophageal cancer, or a combination thereof.

[0021] In another preferred embodiment, the tumor is a urinary system tumor.

[0022] In another preferred embodiment, the tumor is bladder cancer.

[0023] In another preferred embodiment, the combined administration comprises administering miglitol and other tumor therapies to a subject in need thereof.

[0024] In another preferred embodiment, the subject in need is a cancer patient, and the cancer patient has or has not received other tumor therapies.

[0025] In another preferred embodiment, the subject includes: a mammal.

[0026] In another preferred embodiment, the mammal includes a human or a non-human mammal.

[0027] In another preferred embodiment, the non-human mammals include: rodents (such as rats and mice) and primates (such as monkeys).

[0028] In another preferred embodiment, the combined administration includes: (1) administering miglitol and other tumor therapies simultaneously; (2) administering miglitol before other tumor therapies; or (3) administering miglitol after other tumor therapies.

[0029] In a second aspect of the present invention, a pharmaceutical composition is provided, comprising:

[0030] (a1) a safe and effective amount of miglitol as the first active ingredient;

[0031] (a2) a safe and effective amount of another drug for treating tumors as a second active ingredient; and

[0032] (b) a pharmaceutically acceptable carrier.

[0033] In another preferred embodiment, the pharmaceutical composition includes: a solid dosage form, a liquid preparation, or a gel preparation.

[0034] In another preferred embodiment, the pharmaceutical composition includes: an oral dosage form or an injection.

[0035] In another preferred embodiment, the pharmaceutical composition includes: tablets, powders, granules, capsules, lyophilized agents, solutions, and syrups.

[0036] In another preferred embodiment, the other drugs for treating tumors are selected from the following group: chemotherapy drugs, immunotherapy drugs (such as immune checkpoint inhibitors, BCG), targeted drugs, or a combination thereof.

[0037] The chemotherapy drug is a platinum-based chemotherapy combined with gemcitabine.

[0038] In another preferred embodiment, the tumor is a solid tumor.

[0039] In another preferred embodiment, the tumor is selected from the following group: bladder cancer, prostate cancer, breast cancer, thyroid cancer, lung cancer, esophageal cancer, or a combination thereof.

[0040] In another preferred embodiment, the tumor is a urinary system tumor.

[0041] In another preferred embodiment, the tumor is bladder cancer.

[0042] In a third aspect of the present invention, a medicine kit is provided, comprising:

[0043] (i) a first pharmaceutical composition, comprising (a1) a safe and effective amount of miglitol as a first active ingredient; and (b1) a pharmaceutically acceptable carrier;

[0044] (ii) a second pharmaceutical composition, the second pharmaceutical composition comprising (a2) a safe and effective amount of another drug for treating tumors as a second active ingredient; and (b2) a pharmaceutically acceptable carrier;

[0045] Wherein, the first pharmaceutical composition and the second pharmaceutical composition are independent of each other.

[0046] In another preferred embodiment, the first pharmaceutical composition and the second pharmaceutical composition are each independently a solid dosage form, a liquid preparation, or a gel preparation.

[0047] In another preferred embodiment, the first pharmaceutical composition and the second pharmaceutical composition are each independently in the form of an oral dosage form or an injection.

[0048] In another preferred embodiment, the first pharmaceutical composition is an oral dosage form.

[0049] In another preferred embodiment, the other drugs for treating tumors are selected from the following group: chemotherapy drugs, immunotherapy drugs (such as immune checkpoint inhibitors, BCG), targeted drugs, or a combination thereof.

[0050] The chemotherapy drug is a platinum-based chemotherapy combined with gemcitabine.

[0051] In the fourth aspect of the present invention, there is provided a use of an active ingredient combination in the preparation of a drug for treating or alleviating a tumor, characterized in that the active ingredient combination comprises: (a) a first active ingredient, miglitol; and (b) a second active ingredient, other drugs for treating tumors.

[0052] In another preferred embodiment, the other drugs for treating tumors are selected from the following group: chemotherapy drugs, immunotherapy drugs (such as immune checkpoint inhibitors, BCG), targeted drugs, or a combination thereof.

[0053] The chemotherapy drug is a platinum-based chemotherapy combined with gemcitabine.

[0054] In another preferred embodiment, the tumor is a solid tumor.

[0055] In another preferred embodiment, the tumor is selected from the following group: bladder cancer, prostate cancer, breast cancer, thyroid cancer, lung cancer, esophageal cancer, or a combination thereof.

[0056] In another preferred embodiment, the tumor is a urinary system tumor.

[0057] In another preferred embodiment, the tumor is bladder cancer.

[0058] In the fifth aspect of the present invention, a method for treating tumors or cancer is provided, comprising: (1) administering miglitol in combination with other tumor therapies to a subject in need; (2) administering the pharmaceutical composition described in the second aspect of the present invention to a subject in need; and / or (3) administering the drug kit described in the third aspect of the present invention to a subject in need.

[0059] In another preferred embodiment, the tumor is a solid tumor.

[0060] In another preferred embodiment, the subject in need is a cancer patient, and the cancer patient has or has not received other tumor therapies.

[0061] In another preferred embodiment, the subject includes: a mammal.

[0062] In another preferred embodiment, the mammal includes a human or a non-human mammal.

[0063] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS

[0064] Figure 1 The induction effect of miglitol on bladder cancer differentiation was shown. Figure 1 A shows the effect of miglitol on the proliferation, migration and invasion of bladder cancer cells; B and C show the cell connection morphology and quantitative results of cells in the miglitol group and the control group; D shows the muscle invasion ability of cells in the miglitol group and the control group; Figure 1 E shows the differentiation status of cells in the miglitol group and the control group; Figure 1 F shows the progression stage of bladder cancer in the miglitol group and the control group; G shows the bladder volume of mice in the miglitol group and the control group.

[0065] Figure 2 The therapeutic effect of combined use of miglitol in patients with invasive bladder cancer was shown. Figure 2A shows the process of establishing a mouse model of MIBC patients receiving neoadjuvant chemotherapy; B shows the overall survival time of mice, where the red CTR represents the control group that only received NAC, and the blue Mig represents the experimental group that received a combination of NAC and miglitol; C shows the therapeutic effect of the miglitol combined with NAC treatment regimen on mouse tumors; D shows the combined miglitol treatment regimen administered to 3 clinical patients; E and F show the changes in tumor size of 3 clinical patients; G shows the therapeutic effect of the combined therapy of the present invention, controls, and patients in other clinical trials. DETAILED DESCRIPTION

[0066] After extensive and in-depth research, the inventors discovered for the first time that the α-glucosidase inhibitor miglitol can induce differentiation of solid tumor cells, placing tumor cells in a highly differentiated state. On the one hand, it can reduce the plasticity of the tumor and inhibit the malignant progression of the tumor; on the other hand, it can improve the killing efficiency of traditional therapies, thereby increasing the responsiveness of tumor patients to various tumor-killing strategies.

[0067] Specifically, taking bladder cancer as an example, the present invention found that miglitol can significantly inhibit the malignant progression of bladder cancer in both in vivo and in vitro models; miglitol effectively prolonged the survival time of mice in two preclinical models of tumor transplants derived from patients; in addition, in clinical studies, the proportion of patients achieving complete remission significantly increased when miglitol was combined with traditional therapies to treat bladder cancer patients, and no adverse reactions occurred, showing good safety and clinical application prospects. On this basis, the present invention was completed.

[0068] Terms and Abbreviations

[0069] NMIBC: non-muscle invasive bladder cancer

[0070] MIBC: muscle invasive bladder cancer

[0071] NAC: neoadjuvant chemotherapy

[0072] GC: Gemcitabine-cisplatin chemotherapy regimen

[0073] ICI: immune checkpoint inhibitors

[0074] PDX: Patient-derived transplants

[0075] PDOX: Patient-derived orthotopic implants

[0076] pCR: pathological complete response

[0077] CR: Complete remission

[0078] Tumor cell differentiation and therapeutic effects

[0079] Under normal circumstances, cell plasticity is an important mechanism for maintaining tissue and organ homeostasis and function, and its main pathways include stem cell subset expansion, dedifferentiation and transdifferentiation. For tumor tissues, cell plasticity gives cancer cells the ability to change their own phenotype and function according to environmental changes, thereby evading immune recognition, differentiation pressure and killing by various anti-tumor strategies. In addition, in the process of changing their own lineage types, tumors can continue to enter a state of lower differentiation, thereby acquiring malignant characteristics such as invasion, drug resistance and metastasis. When the tumor is in a poorly differentiated or undifferentiated state, it means a stronger ability to proliferate, resist drugs and metastasize. Traditional therapies such as chemotherapy and radiotherapy that aim to directly kill tumor cells cannot effectively kill such cells on the one hand, and even promote the development of tumor cells to a lower degree of differentiation on the other hand.

[0080] Taking bladder cancer as an example, there are 500,000 new cases of bladder cancer worldwide each year, and about 200,000 deaths each year. Among the patients diagnosed for the first time, about 70% are diagnosed with non-muscle invasive bladder cancer (NMIBC), which is relatively less invasive, well differentiated, and has a good five-year survival rate. However, the 5-year recurrence rate of NMIBC is as high as 57%-77%; and 20%-30% of high-risk NMIBC will progress to a poorly differentiated subtype with invasive and metastatic capabilities - muscle invasive bladder cancer (MIBC) when it recurs. The first-line therapy for the clinical treatment of MIBC is neoadjuvant chemotherapy (NAC), which is mainly based on gemcitabine + cisplatin, but the chemotherapy response rate is less than 50%, and the overall survival benefit is only about 10%; because patients lose their functional bladders after surgery, their quality of life is often poor. More importantly, primary MIBC developed from NMIBC has a worse prognosis and a lower response rate to neoadjuvant chemotherapy. Although immune checkpoint inhibitors (ICIs) have shown some promise in bladder cancer, insufficient response rates remain.

[0081] Therefore, in order to promote solid tumor patients to fully benefit from various existing therapies, it is very important to improve the degree of tumor cell differentiation and inhibit tumor plasticity. In the present invention, it is first discovered that miglitol can improve the differentiation level of tumor cells, reduce the malignancy of tumor cells, and improve the killing efficiency of traditional therapies, thereby increasing the response of tumor patients to various tumor killing strategies such as chemotherapy and radiotherapy.

[0082] Miglitol

[0083] Miglitol, or 1-(2-hydroxyethyl)-2-(hydroxymethyl)-3,4,5-piperidintriol, is an α-glucosidase inhibitor that was approved by the Food and Drug Administration (FDA) more than 30 years ago for the treatment of type II diabetes. Miglitol has good pharmacokinetics, no known toxicity, is not decomposed in the body, is ingested and eliminated in its original form, and is almost entirely excreted through urine; it has good water solubility and can be effectively absorbed orally. Clinical studies have shown that long-term oral administration of the drug has no significant effect on the urinary system, cardiovascular system, respiratory system, and blood parameters, and has good safety.

[0084] The present invention finds for the first time that miglitol can induce differentiation of solid tumor cells and improve the therapeutic effects of other tumor therapies. In one embodiment of the present invention, bladder cancer cells are treated with miglitol, and poorly differentiated bladder cancer cells can be converted into a highly differentiated state, proving the induction of miglitol on the differentiation of cells in vitro. In one embodiment of the present invention, for a bladder cancer mouse model, the simultaneous administration of miglitol and neoadjuvant chemotherapy prolongs the overall survival time of the mice and increases the probability of complete pathological remission (pCR). In one embodiment of the present invention, the clinical effect of the combined use of miglitol was tested, and it was found that the complete remission rate of bladder cancer patients who were simultaneously administered miglitol, chemotherapy, and immune checkpoint inhibitors was significantly improved, much higher than the control group that was not co-administered with miglitol.

[0085] Miglitol induces differentiation of solid tumors, inducing poorly differentiated and undifferentiated tumor cells into a highly differentiated state. It has universal characteristics, that is, it does not target a specific mutation to induce differentiation, and can be non-specifically applied to solid tumors including but not limited to bladder cancer.

[0086] Combination therapy of the present invention

[0087] In the present invention, a method for treating solid tumors by combining Miglitol with other tumor therapies is provided. Miglitol can induce differentiation of solid tumor cells and reduce the malignancy of tumor cells, thereby improving the tumor-killing effect of other tumor therapies.

[0088] As used herein, the term "co-administered" or "combined use" refers to administering miglitol and other cancer therapies to the same patient. The administration of miglitol can be performed before, after or simultaneously with the use of the other cancer therapies.

[0089] In the present invention, other tumor therapies include therapies known in the art for treating tumors, including but not limited to chemotherapy, radiotherapy, immunotherapy, surgical treatment, etc. In one embodiment of the present invention, miglitol is administered in combination with a chemotherapeutic drug, including but not limited to platinum-based chemotherapeutic drugs, chemotherapy adjuvant drugs, etc. In one embodiment of the present invention, miglitol is administered in combination with an immune checkpoint inhibitor, including but not limited to PD1, PD-L1, TIGHT, CTLA-4 inhibitors or a combination thereof. Other tumor therapies can be selected according to the specific tumor type, patient condition, etc.

[0090] Taking bladder cancer as an example, miglitol combined with platinum-based neoadjuvant chemotherapy can be used to treat invasive bladder cancer, including but not limited to cisplatin, nedaplatin, carboplatin, combined with gemcitabine; miglitol combined with immune checkpoint inhibitors (PD1, PD-L1, TIGHT and CTLA-4 inhibitors, etc.) can be used to treat invasive bladder cancer; miglitol combined with BCG (bacillus Calmette-Guérin) can be used to treat refractory superficial bladder cancer. The above examples are only used to illustrate the combined therapy of the present invention and do not limit the treatment scope of the combined therapy of the present invention.

[0091] Pharmaceutical composition

[0092] In the present invention, a pharmaceutical composition for treating tumors or cancer is provided, comprising miglitol as a first active ingredient, other drugs for treating tumors as a second active ingredient, and a pharmaceutically acceptable carrier.

[0093] The pharmaceutical composition of the present invention comprises miglitol within a safe and effective amount, a second active drug, and a pharmaceutically acceptable excipient or carrier, wherein "safe and effective amount" means: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects.

[0094] "Pharmaceutically acceptable carrier" refers to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with the targeting promoter of the present invention and with each other without significantly reducing the efficacy of the compound. Some examples of pharmaceutically acceptable carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as ), wetting agents (such as sodium lauryl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.

[0095] There is no particular limitation on the administration route of miglitol or the pharmaceutical composition. Representative administration routes include, but are not limited to, oral administration and parenteral administration (intravenous, intramuscular or subcutaneous).

[0096] Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and acacia; (c) humectants, for example, glycerol; (d) disintegrants, for example, agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) solubilizers, for example, paraffin; (f) absorption accelerators, for example, quaternary ammonium compounds; (g) wetting agents, for example, cetyl alcohol and glyceryl monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.

[0097] Solid dosage forms such as tablets, pills, capsules, pills and granules can be prepared using coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifiers, and the release of the active compound or compounds in such compositions can be delayed in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and waxes. If necessary, the active compound can also be formed into microencapsulated form with one or more of the above-mentioned excipients.

[0098] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage form may contain an inert diluent conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide and oils, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances.

[0099] Compositions for parenteral injection may include physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.

[0100] When using the pharmaceutical composition, a safe and effective amount of the pharmaceutical composition of the present invention is applied to a mammal (such as a human) in need of treatment, wherein the dosage during administration is a pharmaceutically effective dosage. For a person weighing 60 kg, the daily dosage is usually 75 mg to 300 mg, preferably 150 mg (50 mg each time, three times a day). Of course, the specific dosage should also take into account factors such as the route of administration and the health status of the patient, which are all within the skill range of skilled physicians.

[0101] The main advantages of the present invention include:

[0102] (1) The present invention discovered for the first time that miglitol can induce differentiation of solid tumor cells, making the tumor cells at a high differentiation level, that is, reducing the plasticity of tumor cells, thereby making the tumor less malignant and easier to be eliminated by other tumor therapies, thereby improving the patient's response rate to tumor therapies.

[0103] (2) Miglitol of the present invention is a drug that can be clearly used in clinical practice. Without changing the dosage and administration method, it can effectively induce the differentiation of solid tumors (bladder cancer), assist other tumor therapies in producing greater therapeutic benefits, and has clinical safety.

[0104] (3) The method of treating tumors by combined administration of miglitol of the present invention has universal characteristics and can non-specifically transform poorly differentiated and undifferentiated tumor cells into highly differentiated ones. It can be used to treat a variety of solid tumors and has a wide range of applications.

[0105] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended only to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods for the unrecorded specific conditions in the following examples are usually based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, percentages and fractions are weight percentages and weight fractions.

[0106] Example 1: Effect of Miglitol on Differentiation of Bladder Cancer Cells

[0107] To verify the effect of miglitol on bladder cancer plasticity, 50 μM miglitol was added to normal cell culture medium and treated with UMUC3 cells, a bladder cancer cell line, for two weeks. The results showed that drug-treated cells exhibited epithelial cell-like morphology, increased cell connections, and showed a large number of actin microfilaments ( Figure 1 B and C).

[0108] Afterwards, a MIBC patient-derived xenograft (PDX) was transplanted subcutaneously into immunodeficient mice. The re-formed mouse tumors were digested into single-cell suspensions and then cultured in a rat bladder organ culture system. Histological analysis of the culture system at different time points revealed that the tumor cells treated with miglitol were well differentiated and had almost no muscle invasion; while the control group showed a spindle-shaped morphology and muscle invasion ability, indicating that it was in a low-differentiation state with high plasticity ( Figure 1 D).

[0109] Finally, these cells were transplanted orthotopically into the bladder of nude mice using PDOX technology. Similar to the previous experimental results, the cells in the control group showed mesenchymal morphology, highly expressed VIM, and low expression of HLA class II DRα1 chain (HLA-DRA), suggesting that these cells were in an undifferentiated state ( Figure 1 E); however, PDOX treated with miglitol exhibited a papillary phenotype and the progression of bladder cancer was inhibited ( Figure 1 F), the cells were HLA-DRA positive and remained confined to the urethral epithelium. In addition, the bladder volume of mice treated with miglitol was similar to that of normal bladders, while the bladder volume of control mice increased by more than ten times ( Figure 1 G).

[0110] These data suggest that miglitol can transform mesenchymal-like poorly differentiated bladder cancer cells into an epithelial-like highly differentiated state in cellular, semi-ex vivo and in vivo models.

[0111] Example 2: Effect of combined miglitol therapy on mouse models

[0112] Neoadjuvant chemotherapy (NAC) based on platinum drugs remains the most common treatment method in patients with radical bladder cancer (MIBC) and has the highest level of evidence support. However, the therapeutic effect of this standard treatment needs to be improved. In this example, the therapeutic effect of NAC alone (control group) and NAC combined with miglitol (Mig group) on bladder cancer was tested.

[0113] The present invention established a mouse model that simulates MIBC patients and implanted PDX xenograft tumors from two MIBC patients ( Figure 2 A), received neoadjuvant chemotherapy with gemcitabine (Gem) + cisplatin (CIS). PDX was induced into organoids, and then 50μM miglitol (or no miglitol, as a control) was added to the organoid culture system. After two weeks, it was digested into a single cell suspension and transplanted in situ into the mouse bladder. Subsequently, the mice received intravenous injections of cisplatin and gemcitabine in sequence. Mice were given drinking water with or without miglitol by gavage until the last gemcitabine injection. Survival was recorded throughout the process in a double-blind manner.

[0114] The results showed that the overall survival time was significantly prolonged in the PDOX mouse model (HR=0.3429 and 0.2652, Figure 2 B), corresponding to an absolute improvement of 192% and 277%, respectively. Analysis of the bladders of surviving mice revealed that no tumors were found in any of the four surviving mice implanted with PDX-1, indicating that the combination of miglitol and NAC significantly increased the probability of complete pathological remission (pCR) in the mouse model ( Figure 2 C).

[0115] Example 3: Clinical therapeutic effect of combined use of miglitol on bladder cancer

[0116] In the clinical trial, three patients who were diagnosed with MIBC before cystectomy and had no metastasis were enrolled to verify the treatment results of combined use of miglitol. The patients received standard platinum-based chemotherapy combined with immune checkpoint inhibitors (ICI) and took miglitol orally throughout the whole process. Figure 2 D). After completing treatment, all three patients achieved complete remission (CR) and experienced no adverse reactions ( Figure 2 E and Figure 2 F, Figure 2 G first row of data).

[0117] In order to further compare the effects of combined use of miglitol and non-combination miglitol on the remission rate of patients, the above three patients were compared with other patients who received similar treatment regimens but did not include miglitol. Among all MIBC patients with similar diagnosis (tumor stage T2-4NxM0), 9 patients received platinum-based neoadjuvant chemotherapy (including cisplatin, nedaplatin, carboplatin, etc.) plus ICI treatment based on PD-1 / PD-L1 antibodies, of which only 2 achieved complete remission (CR) within 3-4 cycles, which was significantly lower than the proportion of patients in the present invention who received combined use of miglitol ( Figure 2 G second row data).

[0118] In addition, the data of the present invention were compared with recent clinical reports (NCT02690558 and NCT02989584), in which similar patients received gemcitabine-cisplatin chemotherapy plus atezolizumab or pembrolizumab, and the proportion of complete remission was 14 / 39 and 16 / 39, respectively, which were lower than the effect of the regimen of the present invention combined with miglitol ( Figure 2 G third and fourth row data).

[0119] The above results indicate that the combined use of miglitol in the treatment of bladder cancer can significantly improve the therapeutic effect of MIBC patients.

[0120] discuss

[0121] The development of induced differentiation therapy is a difficult problem that needs to be solved urgently in the field of basic research and clinical treatment of solid tumors. Currently, there is only one differentiation therapy that can be used for clinical treatment, which is the use of all-trans retinoic acid and arsenic to treat acute promyelocytic leukemia. The principle is that these two compounds break up the PML-RARα complex with fusion mutations, causing the cells to redifferentiate into granulocytes. Due to genomic defects and immunogenicity, apoptosis or phagocytosis by macrophages occurs, leading to complete remission of APL. However, this method is only applicable to this type of leukemia, not other cancers; even for other blood cancers, there is no similar method.

[0122] There is currently no induced differentiation therapy applied to solid tumors, whose genomic changes are much more complex than APL, and the methods of escaping differentiation pressure are more diverse. Therefore, it is extremely difficult to achieve tumor differentiation in epithelial tumors by targeting specific mutations, and no differentiation therapy for solid tumors can be used clinically so far. The de Sauvage team at Genentech targeted the protein tyrosine phosphatase receptor KR spine protein (PTPRK-RSPO3) fusion mutation in colon cancer and successfully induced differentiation in two PDXs with this mutation in a patient-derived transplant tumor model (PDX). However, this low-frequency mutation is also difficult to generalize to other tumors. Christofori et al. from the University of Basel transdifferentiated highly dedifferentiated breast cancer cells into adipose tissue, which provided new biological possibilities, but was difficult to carry out in actual clinical applications; Kong Mei's team at the University of California, Irvine, successfully achieved the differentiation of colorectal cancer by supplementing α-ketoglutarate, an intermediate product of the tricarboxylic acid cycle, but the effect was not enough to significantly benefit patients; Professor Chen Chong's team at Sichuan University in my country found that inhibiting tissue plasminogen activator can achieve terminal squamous transdifferentiation of bladder cancer, but the inhibitors of this molecule cannot be used in humans.

[0123] The present invention describes a drug that can be clearly used in clinical practice, which can effectively induce the differentiation of solid tumors without changing the dosage and administration method. With the differentiation of tumors, the plasticity of tumor cells will be eliminated, thereby reducing the invasion, metastasis, stem cell characteristics and drug resistance of tumors and other malignant characteristics, and assisting standard therapy to produce greater therapeutic benefits.

[0124] At the same time, the present invention has a universal feature, that is, it does not target a specific mutation to induce differentiation. Escaping the fate of differentiation is a key mechanism for the occurrence and development of various cancers; cancers originating from epithelial tissues, that is, solid tumors, often have complex mutations and high diversity. Therefore, methods targeting a single or several key mutant genes are not suitable for the development of inducing differentiation therapy for solid tumors. The method described in the present invention can non-specifically transform poorly differentiated and undifferentiated bladder cancer cells into highly differentiated ones, and thus represents a method that is more suitable for solid tumors.

[0125] In addition, the present invention has clinical feasibility. Miglitol was invented in the 1990s and has been clinically used for more than 30 years without any serious adverse reactions reported. The compound does not decompose in the body and is ingested and excreted in its original form; it is almost entirely excreted through urine, so it is particularly suitable for urinary system tumors; it has good water solubility and can be effectively absorbed orally. Therefore, in the application scenario described in the present invention, miglitol only needs to be taken orally and in standard doses to achieve the purpose of the present invention.

[0126] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. A use of an α-glucosidase inhibitor, Miglitol, characterized in that: For preparing an agent or a pharmaceutical composition, the agent or the pharmaceutical composition is used for an application selected from the following group: (1) Improve the differentiation of tumor cells; (2) reducing the malignancy of tumor cells; and / or (3) Combined administration with other tumor therapies to treat or alleviate tumors.

2. The use according to claim 1, characterized in that The other tumor therapies include: chemotherapy, radiotherapy, immunotherapy, surgical treatment, targeted drug therapy, or a combination thereof.

3. The use according to claim 1, characterized in that The chemotherapy is neoadjuvant chemotherapy.

4. The use according to claim 1, characterized in that The tumor is a solid tumor.

5. The use according to claim 1, characterized in that The immunotherapy includes administering immune checkpoint inhibitors and / or Bacillus Calmette-Guérin (BCG), wherein the immune checkpoint inhibitors include: PD-1 / PD-L1 inhibitors, TIGHT inhibitors, CTLA-4 inhibitors, or a combination thereof.

6. The use according to claim 1, characterized in that The targeted drugs include: FGFR inhibitors, VEGF inhibitors, EGFR inhibitors, antibody-drug conjugates (ADCs), or combinations thereof.

7. The use according to claim 1, characterized in that The combined administration includes: (1) administering miglitol simultaneously with other tumor therapies; (2) administering miglitol before other tumor therapies; or (3) administering miglitol after other tumor therapies.

8. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises: (a1) a safe and effective amount of miglitol as the first active ingredient; (a2) a safe and effective amount of another drug for treating tumors as a second active ingredient; and (b) a pharmaceutically acceptable carrier.

9. A medicine box, characterized in that: The kit comprises: (i) a first pharmaceutical composition, comprising (a1) a safe and effective amount of miglitol as a first active ingredient; and (b1) a pharmaceutically acceptable carrier; (ii) a second pharmaceutical composition, the second pharmaceutical composition comprising (a2) a safe and effective amount of another drug for treating tumors as a second active ingredient; and (b2) a pharmaceutically acceptable carrier; Wherein, the first pharmaceutical composition and the second pharmaceutical composition are independent of each other.

10. Use of an active ingredient combination in the preparation of a drug for treating or alleviating tumors, characterized in that: The active ingredient combination comprises: (a) a first active ingredient, miglitol; and (b) a second active ingredient, other drugs for treating tumors.

Citation Information

Patent Citations

  • Compositions for cancer treatment

    CN1741821A

  • Cancer treatment by metabolic modulations

    US20050202559A1

  • Compositions and Methods of Treating and Preventing Lung Cancer and Lymphangioleiomyomatosis

    US20130004436A1

  • Cancer Drug and Uses

    US20140199296A1

  • Methods for treating small cell neuroendocrine and related cancers

    US20220244263A1